IAS2023: 2593

JABS 48 week results: Implementation of long-acting cabotegravir and rilpivirine in vulnerable populations with complex needs

Mina John^{1,2*}, Leah Williams¹, Genevieve Nolan¹, Morgan Bonnett¹, Ailsa Allen¹, Alison Castley^{1,2}, David Nolan¹

Department of Clinical Immunology, Royal Perth Hospital, Western Australia ² PathWest, WA Health, Western Australia

*Corresponding author: Mina.John@health.wa.gov.au

Background

- Long-acting cabotegravir (CAB) + rilpivirine (RPV) is approved for use in virologically suppressed people living with HIV infection.
- The inJectable Antiretroviral feasiBility Study (JABS) evaluated the effectiveness of CAB+RPV in a large tertiary hospital ambulatory care setting in Perth, Western Australia.
- Participants with complex medical needs, social vulnerability and historical non-adherence, who are under-represented in registrational trials but may derive particular engagement and adherence benefits, were included in the enrolment.
- A multidisciplinary 'REACH' service comprising a Senior Social Worker, HIV Nurse Practitioner, and Immunology Welfare Assistant

Methods

• JABS is a 48-week, single centre, single arm, open label study of long acting CAB 600mg plus RPV 900mg every 2 months to adults with treated HIV-1 infection.


• Oral bridging and discontinuations

- Oral lead in was included, as per recommendations at the time of study commencement.
- Primary endpoint: Proportion of attendances/delivery of injections within a fourteen-day dosing window over 12 months.
- Secondary and exploratory endpoints:
 - Missed/rescheduled appointments
 - Virological failures
- Adverse events
- Participant related outcomes
- Changes to service delivery
- Qualitative PRO data were obtained with questionnaires administered to participants at day 1, week 8, week 24 and week 48 as well as semi-structured interviews at Day 1 and week 48.
 - Questionnaires measured medication adherence (before JABS), treatment satisfaction pre and post commencing LA therapy,



who liaise with the medical team as well as other agencies, provided individualised support to participants.

Figure 1. RPH REACH Service



and injection experience (specifically surrounding pain, local reactions and acceptability). Semi-structured interviews discussed participants experiences with oral therapy and LA therapy, including challenges, facilitators, and suggestions for improvement.


Table 1. JABS Study Design

Timeline	Day 1	Week 4	Week 8	Week 16	Week 24	Week 32	Week 40	Week 48
Treatment Oral lead-in Start CAB + RPV LA								
	otart	Dose 1	Dose 2	Dose 3	Dose 4	Dose 5	Dose 6	Dose 7
Data Collection		•	• ×	•		•	•	
Medication adhe		Semi-structured	interview Blo	od monitoring tes		satisfaction surve	v VInjection ex	narianca surve

Results


Baseline Characteristics

Table 2. Participant Demographics (n=60)




Adherence

Figure 5. Adherence to Injection Schedule




Patient Reported Outcomes

Figure 7. Injection Experience




BMI 26.22 4.17 18.75 39.85

Figure 2. Participant Treatment History (n=60)



*Other included Descovy/Nevirapine; Descovy/Dolutegravir; Kaletra/Tenofovir/Lamivudine

Figure 3. Complexity Risk Factors



*Hepatitis C and/or Cancer also measured as factor but was reported by 0 participants


- Days from target date
- Overall, 97.2% (n=384) of injections occurred within the dosing window, 97.7% (n=386) of occurred within the dosing window or earlier, and 2.3% (n=9) occured late.
 - Most common reason for late injections were being unable to attend due to work commitments (n=3) or being difficult to engage/contact (n=3)
 - Mean number of days from target date:0.4; range: 8-41 days
 - Dose administered 41 days after target date was due to an injection site reaction (hard lump) causing a delay in injection dose. Oral therapy (oral CAB+RPV) was used during this period.

Virological Outcomes

- Participants who completed the study at week 48: n=54
- 98.15% of participants had HIV RNA <40 copies/ml at week 48 (n=53) • 1 participant had HIV RNA of 55 copies/ml at week 48

• No virological failures (>200 copies/ml) during course of entire study

Figure 6. Viral Load Profile





Adverse Events

5.0	acceptable	acceptable	Very dissatisfied	Extremely	Definitely not
*lf no	ot involved in JAE	3S			

- 21-question survey covering 5 domains: before/during the injections, after the injections, local reactions, pain, overall experience. Overall experience (questions 17, 18, 19, 20, 21) shown above.
- Completed at participants 2nd (week 8) and final (week 48) injection appointments.

Figure 8. Treatment Satisfaction





 Assessed over 12 domains: overall satisfaction, HIV control, side effects, demands, convenience, flexibility, understanding of HIV, lifestyle, likelihood of recommendation to others, continuation, ease or difficulty, and discomfort/pain.

• 0-6 likert scale used at Baseline and Week 24, -3-+3 likert scale used at Week 48 to assess change.


Participant Experience

Put yourself in our shoes. The daily reminder can be debilitating. We get to live again. My mum has noticed a change in me. I'm planning trips, I'm making changes.

For the first time in 14 years, I celebrated my birthday without thinking about HIV at all

- CMA, Crystal methamphetamine; AOD, Alcohol and Other Drugs
- Calculated using a validated complexity rating score¹
- This tool did not consider other factors which may impact complexity including housing status, family commitments, travel issues, work commitments (including fly-in-fly-out work).

Figure 4. Level of Engagement and Support (n=60)



*Formal supports included Public Health, Mental Health or Community Case Management Staff assessed participants as requiring either a "standard" or "enhanced" service level based upon their previous adherence and engagement as well as complexity factors that were not considered in the complexity score tool.

Table 3. Adverse Events

	Grade	IM CAB + RPV (N=395)	Oral Lead In (N=60)
Drug-related adverse events	Grade 1-2	0	1(1.7%)*
Didg-related adverse events	Grade 3	0	0
Injection site reactions	Grade 1-2	115(29.1%)	N/A
injection site reactions	Grade 3	3(0.8%)	N/A
Discontinuation due to advers	1(1.7%)	1(1.7%)	
Discontinuation for other rea	4 (6.7%)	0	

*3 participants reported difficulties during the oral lead-in due to being unable to take their PPI medication (not considered a drug-related AE)

** Discontinuation due to anticoagulant therapy (1), hepatitis B diagnosis (1), fertility management (1), personal health beliefs (1)

- 1 participant discontinued during the oral lead-in, reporting difficulties sleeping (as well as effects of being unable to take PPI medication (for reflux). Unable to discern if drug-related as participant reported current stressors likely impacting their sleep.
- 1 participant discontinued due to ISR, reporting the injection site pain was interfering with their exercise regimen.

I will never go back to pills. I have freedom that I haven't had since before I was diagnosed.

I never expected it to make a difference but it really has lifted a weight off my shoulders I didn't realise was there.

Freedom of not having to think about diagnosis has changed everything. Friends have noticed I'm more like the old me. I even think I might start dating again.

Being able to forget that I have HIV after being positive for 15 years is such a blessing.

Conclusions

• There is a high amount of interest in use of CAB+RPV among people living with HIV including those with risk factors for non-adherence to antiretroviral therapy

- Adherence to, and efficacy of, 2 monthly CAB+RPV in a real-world Australian population is comparable to those in phase III randomised clinical trials.
- People with identified complex needs, social vulnerability and historical nonadherence achieved the same levels of adherence, and virological suppression, as the wider study population.

Acknowledgements: This study was supported by an investigator initiated grant (ViiV Healthcare). The authors wish to thank all those involved in JABS, including participants, clinical and administrative staff of the Department of Clinical Immunology Royal Perth Hospital, Western Australia. Presented at IAS 2023, the 12th IAS Conference on HIV Science

References: 1. Bulsara SM et al. Int J STD AIDS. 2019 Nov;30(13):1265-1274. **Study approved** by Royal Perth Hospital Ethics Committee (HREC #RGS0000004857)

